💊 Blueprint Medicines: Positive Momentum and Growth Prospects! 📊 Analysis NASDAQ:BPMC :
Financial Performance: 90% YoY growth in net-product revenues from U.S. sales of Ayvakit, a drug for certain cancers.
Market Prospects: Positive market response to Ayvakit's unique clinical profile.
CEO's Confidence: CEO's confidence in the company's future contributes to i